These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 9855525

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R.
    Immunopharmacology; 2000 Jul 20; 48(2):95-100. PubMed ID: 10936507
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Neutralizing antibodies to multiple sclerosis treatments.
    Rossman HS.
    J Manag Care Pharm; 2004 Jun 20; 10(3 Suppl B):S12-9. PubMed ID: 15253685
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, Milano E, Melis F, Giordana MT.
    J Neurol Neurosurg Psychiatry; 2002 Aug 20; 73(2):148-53. PubMed ID: 12122172
    [Abstract] [Full Text] [Related]

  • 11. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis.
    Vartanian TK, Zamvil SS, Fox E, Sorensen PS.
    Neurology; 2004 Dec 14; 63(11 Suppl 5):S42-9. PubMed ID: 15596736
    [Abstract] [Full Text] [Related]

  • 12. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
    Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Di Marco P, Gasperini C, Fieschi C, Dianzani F.
    J Neurol Sci; 1999 Oct 15; 168(2):131-6. PubMed ID: 10526196
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
    Cook SD, Quinless JR, Jotkowitz A, Beaton P, Neutralizing Antibody Study Group.
    Neurology; 2001 Sep 25; 57(6):1080-4. PubMed ID: 11571337
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.